CD206-Targeted Liposomal Myelin Basic Protein Peptides in Patients with Multiple Sclerosis Resistant to First-Line Disease-Modifying Therapies: A First-in-Human, Proof-of-Concept Dose-Escalation Study - «Национальный агрегатор открытых репозиториев российских университетов» (НОРА)

Материалов:
1 005 012

Репозиториев:
30

Авторов:
761 409

расширенный поиск

CD206-Targeted Liposomal Myelin Basic Protein Peptides in Patients with Multiple Sclerosis Resistant to First-Line Disease-Modifying Therapies: A First-in-Human, Proof-of-Concept Dose-Escalation Study

Belogurov A., Zakharov K., Lomakin Y., Surkov K., Avtushenko S., Kruglyakov P., Smirnov I., Makshakov G., Lockshin C., Gregoriadis G., Genkin D., Gabibov A., Evdoshenko E.

Дата публикации: 2016

Дата публикации в реестре: 2020-03-01T01:25:08Z

Аннотация:

Ключевые слова:
Clinical trial, Liposomes, Mannose, MRI, Myelin basic protein, Xemys

Тип: Article

Источник: SCOPUS19337213-2016-13-4-SID84975221908

Другие версии документа

CD206-Targeted Liposomal Myelin Basic Protein Peptides in Patients with Multiple Sclerosis Resistant to First-Line Disease-Modifying Therapies: A First-in-Human, Proof-of-Concept Dose-Escalation Study CD206-Targeted Liposomal Myelin Basic Protein Peptides in Patients with Multiple Sclerosis Resistant to First-Line Disease-Modifying Therapies: A First-in-Human, Proof-of-Concept Dose-Escalation Study CD206-Targeted Liposomal Myelin Basic Protein Peptides in Patients with Multiple Sclerosis Resistant to First-Line Disease-Modifying Therapies: A First-in-Human, Proof-of-Concept Dose-Escalation Study

Связанные документы (рекомендация CORE)